Sanofi appoints Peter Guenter senior VP, Europe
pharmafile | June 28, 2011 | Appointment | Manufacturing and Production, Research and Development, Sales and Marketing | appointment, manufacturing and production, research and development, sales and marketing
Sanofi has promoted Peter Guenter to senior vice president, Europe, with effect from 15 July.
He is currently general manager for the company in Germany, Switzerland and Austria and in his new role he succeeds Belen Garijo, who leaves Sanofi for a global leadership role in another pharma company.
Sanofi’s president of global operations Hanspeter Spek said: “I would like to sincerely express my gratitude to Belen for her dedication to the company over the last 15 years. With her combination of experience, skill, passion and commitment, Belen was able to drive the transformation of Sanofi in Europe over the past several years. We wish her all the best for her new professional opportunity.
“The depth of knowledge and experience Peter gained through his previous management roles in Germany and in Europe, as well as his general business acumen make him ideally suited to lead Sanofi’s operations in Europe.”
Peter began his career in Sales at SmithKline in 1986 and moved to Sanofi in 1995. He subsequently held various positions in France, Europe and Global Marketing.
In 2000, he was appointed general manager Belgium and then VP for Eastern Europe, Northern Europe & Scandinavia. In 2008, he was appointed general manager, commercial operations for Germany, and since 2011, he has been general manager for the multi-country organisation for Germany, Switzerland and Austria.
Related Content
PlasmidFactory founder Dr. Martin Schleef honoured with the NRW Innovation Award 2025
The founder and long-standing CEO of PlasmidFactory, Dr. Martin Schleef, was honoured in Düsseldorf with …
Rotzinger launches modular filling and capping platform for over-the-counter products
Rotzinger PharmaPack has launched a new filling and capping platform called VarioFill, designed to handle …
AAX Biotech announces collaboration for cardiovascular antibody therapy
Swedish biotech firm AAX Biotech has entered a new collaboration focused on the development of …
